Frequently Asked Questions As of July 2026, retatrutide has completed four Phase 3 readouts: TRIUMPH-4 (28.7% weight loss in knee OA population, December 2025), TRIUMPH-1 (28.3% weight loss in 2,339 general obesity patients, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c and 16.8% weight loss in 537 T2D patients, June 2026), and the TRIUMPH-1 sleep apnea substudy (60.6% AHI reduction, June 2026)
Este aminocido produzido no corpo e tambm encontrado em pequenas quantidades em certos tipos de alimentos, como produtos de origem animal
Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents
Goldstein, A.L., Hannappel, E